Sulprostone

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Sulprostone
Accession Number
DB12708
Type
Small Molecule
Groups
Investigational
Description

Sulprostone has been used in trials studying Abortion, Induced.

Structure
Thumb
Synonyms
Not Available
External IDs
CP-34,089 / CP-34089 / ZK 57 671 / ZK-57671
Categories
UNII
501Q5EQ1GM
CAS number
60325-46-4
Weight
Average: 465.56
Monoisotopic: 465.182123516
Chemical Formula
C23H31NO7S
InChI Key
UQZVCDCIMBLVNR-TWYODKAFSA-N
InChI
InChI=1S/C23H31NO7S/c1-32(29,30)24-23(28)12-8-3-2-7-11-19-20(22(27)15-21(19)26)14-13-17(25)16-31-18-9-5-4-6-10-18/h2,4-7,9-10,13-14,17,19-20,22,25,27H,3,8,11-12,15-16H2,1H3,(H,24,28)/b7-2-,14-13+/t17-,19-,20-,22-/m1/s1
IUPAC Name
(5Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3R)-3-hydroxy-4-phenoxybut-1-en-1-yl]-5-oxocyclopentyl]-N-methanesulfonylhept-5-enamide
SMILES
CS(=O)(=O)NC(=O)CCC\C=C/C[C@@H]1[C@@H](\C=C\[C@@H](O)COC2=CC=CC=C2)[C@H](O)CC1=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AceclofenacThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Aceclofenac.
AcemetacinThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Acemetacin.
Acetylsalicylic acidThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Acetylsalicylic acid.
AlclofenacThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Alclofenac.
AlminoprofenThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Alminoprofen.
AminophenazoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Aminophenazone.
AntipyrineThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Antipyrine.
AntrafenineThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Antrafenine.
AzapropazoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Azapropazone.
BalsalazideThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Balsalazide.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
5312153
PubChem Substance
347828906
ChemSpider
4471583
ChEBI
135755
ChEMBL
CHEMBL1472830
ZINC
ZINC000004474665
Wikipedia
Sulprostone
ATC Codes
G02AD05 — Sulprostone

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Unknown StatusNot AvailableAbortion induced / Pregnancy Termination1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0296 mg/mLALOGPS
logP1.97ALOGPS
logP1.33ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)4.08ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area130 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity121.9 m3·mol-1ChemAxon
Polarizability48.36 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as prostaglandins and related compounds. These are unsaturated carboxylic acids consisting of a 20 carbon skeleton that also contains a five member ring, and are based upon the fatty acid arachidonic acid.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Fatty Acyls
Sub Class
Eicosanoids
Direct Parent
Prostaglandins and related compounds
Alternative Parents
Phenoxy compounds / Phenol ethers / Alkyl aryl ethers / Cyclopentanols / Organosulfonic acids and derivatives / Aminosulfonyl compounds / Cyclic ketones / Cyclic alcohols and derivatives / Carboxylic acids and derivatives / Organopnictogen compounds
show 3 more
Substituents
Prostaglandin skeleton / Phenoxy compound / Phenol ether / Alkyl aryl ether / Monocyclic benzene moiety / Cyclopentanol / Benzenoid / Aminosulfonyl compound / Sulfonyl / Organosulfonic acid or derivatives
show 18 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 17:42 / Updated on March 01, 2020 21:17

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates